GlassScriptPhysician profile
Adam Jason Waldman
NPI 1952351025
$40,022.80
in general payments reported to CMS, 2019-2025
35 companies · $1,691 in 2025
The $1,691 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,621 · 2020: $3,651 · 2021: $12K · 2022: $9,966 · 2023: $7,749 · 2024: $2,082 · 2025: $1,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,500 · Food and Beverage: $4,968 · Gift: $53.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,500.00 |
| Food and Beverage | $4,967.96 |
| Gift | $53.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $34,523.75 | 2019-2023 | Definity |
| Kestra Medical Technology Services, INC. | $533.18 | 2023-2025 | Assure Wcd |
| Abbott Laboratories | $513.93 | 2019-2024 | Cardiomems |
| Boston Scientific Corporation | $482.95 | 2022-2025 | Watchman Access System, Bodyguardian, Lux-Dx Insertable Cardiac Monitor |
| Astrazeneca Pharmaceuticals LP | $389.01 | 2020-2025 | Farxiga, Wainua |
| Amgen INC. | $329.77 | 2023-2025 | Repatha, Repatha |
| Shockwave Medical, INC | $313.50 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $274.02 | 2019-2025 | |
| Esperion Therapeutics, INC. | $269.66 | 2023-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $253.13 | 2023-2024 | Xarelto |
| Medtronic, INC. | $200.96 | 2023-2024 | Venaseal, Hawkone |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.35 | 2024-2025 | Jardiance |
| Abiomed | $190.28 | 2024-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $183.55 | 2023-2025 | |
| Atricure, INC. | $175.55 | 2024-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $161.43 | 2024-2025 | Onpattro |
| Penumbra, INC. | $153.42 | 2025 | Penumbra System |
| E.R. Squibb & Sons, L.L.C. | $139.40 | 2023-2025 | Camzyos, Eliquis |
| Medtronic Vascular, INC. | $111.40 | 2019 | |
| Merck Sharp & Dohme LLC | $97.43 | 2023-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $72.86 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.54 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $58.17 | 2024 | Arcalyst |
| Biosense Webster, INC. | $54.32 | 2024 | Nuvision Ice Catheter |
| Biotronik INC. | $54.15 | 2023 | Acticor 7 Vr-T Dx, Biomonitor |
| Philips North America LLC | $37.54 | 2024 | (5091) Amb Mon & Diag Und |
| Kiniksa Pharmaceuticals, LTD. | $32.95 | 2023 | Arcalyst |
| Ge Healthcare | $25.18 | 2025 | |
| Ekos Corporation | $24.79 | 2019 | |
| Scpharmaceuticals INC. | $24.47 | 2024 | |
| Bridgebio Pharma, INC. | $20.94 | 2025 | Attruby |
| Novo Nordisk INC | $19.05 | 2024 | Ozempic |
| Cvrx, INC. | $16.87 | 2024 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $14.92 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.38 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Waldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.